FINWIRES · TerminalLIVE
FINWIRES

Dollar General Poised to Meet Market's Bar for Comparable Sales Growth in Q1, UBS Says

By

Dollar General (DG) is expected to meet the market's bar for 2% comparable sales growth in Q1, with the company likely to point out that the quarter started out slow due to the impact of the storms early in the three-month period, UBS said in a note emailed Wednesday.

With regard to its guidance, the company is expected to reiterate its full year comp guidance of 2.2% to 2.7%, UBS said. Additionally, Dollar General could bump up the low end of its EPS guidance of $7.10 to $7.35, as a show of conviction in its forecast, according to the note.

The company will reiterate its opportunity to realize its long-term operating margin guidance of 6% to 7%, UBS said, adding that it is forecasting a 5.3% operating margin this year, 5.7% in 2027, and 5.9% in 2028.

UBS noted that Dollar General is beginning to see meaningful tailwinds from newer businesses like e-commerce and retail media, with e-commerce potentially accounting for 20% to 25% of comp growth looking ahead.

Dollar General is scheduled to report its Q1 results on June 2.

UBS maintained its buy rating with a $168 price target.

Price: $105.52, Change: $+1.91, Percent Change: +1.84%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS